As companies bail out of the inhaled insulin business -- most recently Pfizer, which lost $2.8 billion before throwing Exubera overboard -- one small firm believes there is an alternative to pills, injections and inhalers. Generex, a Worcester, Mass.-based company, believes there's an opportunity for insulin delivery...
DiaMedica Inc. (TSX VENTURE: DMA), a drug discovery and clinical development company focused on a novel approach to treating type 2 diabetes, today announces last patient in for the phase II proof of concept clinical trial with DM-99, the Company's third drug candidate to enter phase II human trials. The...
Byline: By DAVID LOCKWOOD Sports Reporter THAT man Read has again put down a very useful marker as he bids to notch the highest break of the season once more in the SMiles Huddersfield Open Snooker League. Huddersfield Open champion and Lindley WMC star Robert Read...
VALENCIA, Calif., Dec. 18 /PRNewswire-FirstCall/ -- MannKind Corporation today released preliminary top-line results from two pivotal Phase 3 clinical studies of AFRESATM, the company's ultra rapid acting insulin product (Studies 102 and 030). The protocols for these studies were reviewed and prospectively approved by the FDA under...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/55a1c8/learning_autodesk) has announced the addition of John Wiley and Sons Ltd's new report "Learning Autodesk Maya 2009 The Modeling & Animation Handbook: Official Autodesk Training Guide" to their offering. Official Autodesk Training Guide This exceptional, full-color Autodesk Maya Press title...
Significant Weight Loss Achieved and Maintained by Diabetic Subjects Treated with Qnexa over One-Year Continual Reduction in HbA1c Observed Throughout the Year of Treatment in Qnexa Subjects MOUNTAIN VIEW, Calif. -- VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization...
ALR Technologies Inc. (OTCBB: ALRT) announcesthe initial results from the ECHO Healthcare Education Foundation ofAlabama comprehensive diabetes intervention program. The program,sponsored by ALRT, shows significant reduction in A1c values. Participants in the program for three months showed statisticallysignificant changes in: -- Rates of self-monitoring of blood glucose-- ...
Measurement of hemoglobin A1c (Hb A,c)2 is a fundamental component of the management of patients with diabetes mellitus. Hb A^sub 1c^ measurement provides an indication of chronic exposure to glucose and is extensively used for both monitoring long-term glycemic status and evaluating whether an individual patient has attained adequate metabolic...
- Product Extremely Well Tolerated - MONTREAL, Dec. 3 /PRNewswire-FirstCall/ -- ConjuChem Biotechnologies, Inc. (TSX:CJB) announced preliminary results today showing that its Type 2 diabetes product, PC-DACTM:Exendin-4, achieved statistically significant reductions in HbA1c and weight in its two Phase II clinical trials. Commenting on the...
Company to Submit NDA for Lead Product, Metgluna[TM] CAMBRIDGE, Mass. -- Elixir Pharmaceuticals, Inc., announced today positive results from a pivotal phase III clinical study of the Company's oral formulation of mitiglinide administered in combination with metformin for the treatment of patients with type 2 diabetes. The study...
Less than one tenth of one percent of labs in India are CAP and NABL accredited Quest Diagnostics' laboratory also becomes one of only five labs in India to achieve NGSP certification for Hemoglobin A1c testing for diabetes MADISON, N.J. and GURGAON, India, Nov. 17 ...
First laboratory to be certified for A1c testing using dried blood spot specimens BASKING RIDGE, N.J., Nov. 11 /PRNewswire/ -- Heritage Labs International LLC, a division of Hooper Holmes , today announced certification of their hemoglobin A1c testing methods by the National Glycohemoglobin Standardization Program NGSP. ...
- New labeling reinforces strong safety profile of Ranexa - - Conference call scheduled for 8:00 a.m. ET/5:00 a.m. PT - PALO ALTO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that the U.S. Food and Drug Administration FDA has approved a...
SYDNEY, Australia & AUCKLAND, New Zealand & BOULDER, Colo. -- Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today updated shareholders at their Annual General Meeting in Adelaide, Australia on the Phase I/IIa clinical trial of DiabeCell([R]), LCT's lead product candidate for the treatment of insulin dependent (Type 1) diabetes....
A panel of expertsconvened by the American Diabetes Association and the European Associationfor the Study of Diabetes has issued updated treatment recommendations fortype 2 diabetes, in a consensus statement being published online today inthe journals Diabetes Care and Diabetologia. The revisions to the diabetes treatment algorithm, first published in 2006,provide...
A stepped-up care approach is outlined in updated treatment recommendations for type 2 diabetes released Wednesday by the American Diabetes Association and the European Association for the Study of Diabetes. Lifestyle changes and the drug metformin remain the recommended initial treatment to help people newly diagnosed with type 2 diabetes...
Today, at the Canadian Diabetes AssociationCongress, physicians will get a first-time look at more detailed resultsfrom a phase 3b clinical study (LEADTM 6) released by Novo Nordisk (NYSE: NVO) comparing the investigational new drug liraglutide to exenatide. Thestudy showed that liraglutide, a human GLP-1 analog, administered oncedaily was significantly more...
MONTREAL, Oct. 17 /PRNewswire-FirstCall/ -- Today, at the Canadian Diabetes Association Congress, physicians will get a first-time look at more detailed results from a phase 3b clinical study (LEADTM 6) comparing the investigational new drug liraglutide to exenatide. The study showed that liraglutide, a human GLP-1 analog administered once...
DiaMedica Inc. (TSX VENTURE: DMA), a drug discovery and development company focused on a novel approach to treating Type 2 diabetes has announced that it has granted 75,000 incentive options to certain officers or directors of the Company priced at $0.70. The options are set to expire five years from...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/a1c452/global_wind_power) has announced the addition of the "Global Wind Power Report 2008" report to their offering. Today, fossil fuels like oil and natural gas make up to two third of all the energy used in the world. Since most of these resources...
